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Human Leukocyte Antigen 
alleles associated with Myalgic 
encephalomyelitis/chronic fatigue 
Syndrome (Me/cfS)
Asgeir Lande1,2*, Øystein fluge3, Elin B. Strand4,5, Siri T. flåm1, Daysi D. Sosa6, Olav Mella3, 
torstein egeland2,7, Ola D. Saugstad8, Benedicte A. Lie1,2,7 & Marte K. Viken1,7
the etiology and pathogenesis of Myalgic encephalomyelitis/chronic fatigue Syndrome (Me/cfS) are 
unknown, and autoimmunity is one of many proposed underlying mechanisms. Human Leukocyte 
Antigen (HLA) associations are hallmarks of autoimmune disease, and have not been thoroughly 
investigated in a large ME/CFS patient cohort. We performed high resolution HLA -A, -B, -C, -DRB1, 
-DQB1 and -DPB1 genotyping by next generation sequencing in 426 adult, Norwegian ME/CFS 
patients, diagnosed according to the Canadian Consensus Criteria. HLA associations were assessed by 
comparing to 4511 healthy and ethnically matched controls. Clinical information was collected through 
questionnaires completed by patients or relatives. We discovered two independent HLA associations, 
tagged by the alleles HLA-C*07:04 (OR 2.1 [95% CI 1.4–3.1]) and HLA-DQB1*03:03 (OR 1.5 [95% CI 1.1–
2.0]). These alleles were carried by 7.7% and 12.7% of ME/CFS patients, respectively. The proportion 
of individuals carrying one or both of these alleles was 19.2% in the patient group and 12.2% in the 
control group (OR 1.7 [95% CI 1.3–2.2], pnc = 0.00003). ME/CFS is a complex disease, potentially with a 
substantial heterogeneity. We report novel HLA associations pointing toward the involvement of the 
immune system in ME/CFS pathogenesis.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disabling disorder characterized by med-
ically unexplained fatigue, post-exertional malaise and a variety of additional symptoms, such as chronic pain, 
sleep disturbances and cognitive difficulties. ME/CFS is diagnosed on clinical grounds alone, and different sets 
of criteria specify the mandatory symptoms as well as recommendations for the exclusion of differential diagno-
ses1–3. The specificity and validity of different diagnostic criteria have been questioned, yet there is no agreement 
on the level of heterogeneity in ME/CFS, and there is no consensus on how to categorize different subgroups4–8.
The pathogenesis and etiology of ME/CFS are unknown, with several models having been proposed9. One 
central hypothesis states that autoimmunity is part of the pathophysiology10,11. ME/CFS has been reported to be 
partly heritable12,13, consistent with a multifactorial etiology dependent on both genetic and environmental fac-
tors. This is the prevailing model for a vast number of diseases, including established autoimmune diseases (AID). 
Several publications report immunological alterations among ME/CFS patients, e.g. changes in natural killer 
(NK) cell function14,15, cytokine levels16,17, and DNA methylation patterns consistent with immune dysregula-
tion18. Some of these findings have failed to reproduce in other studies, which could be due to differences in meth-
odology, the complexity and heterogeneity of ME/CFS, and lack of power due to small sample sizes19. Resultingly, 
the autoimmunity hypothesis warrants further evaluation. A characteristic feature of AID is genetic association 
with certain human leukocyte antigen (HLA) alleles20. Thus, a thorough investigation of HLA associations in ME/
CFS is relevant, although HLA associations per se cannot be used as evidence regarding disease etiology21. Studies 
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of HLA associations in CFS have been published, but with great variation in patient inclusion criteria and HLA 
typing methodology22–30. No reproducible, significant associations are evident across these studies. In the largest 
study, including 110 patients, the strongest significant association was with HLA-DQ3 with an odds ratio (OR) of 
1.8 (95% CI 1.2–2.8)22. Associations with HLA alleles DQA1*01, DRB1*13:01 and DQB1*06:02 have also been 
reported25,27,29. The great majority of these studies include less than 50 patients, and are underpowered for the 
detection of moderate to weak associations. Hence, in this study we aimed to conduct a comprehensive investiga-
tion of HLA associations in a large ME/CFS cohort, applying modern, high resolution HLA typing.
Results
Characterization of patient and control groups. We included 426 ME/CFS patients and 4511 healthy, 
ethnically matched controls. All patients had been diagnosed in Norway according to the 2003 Canadian 
Consensus Criteria2, except for four patients where the similarly strict 2010 International Consensus Criteria3 
were applied. Demographic and clinical characteristics of patients and controls are shown in Table 1. The mean 
age at diagnosis for ME/CFS patients was 34.7 years, 82.8% were female, and most patients (45.5%) had a disease 
duration of 5–10 years, from symptom debut to inclusion. 12.5% of the patients had severe or very severe disease 
(bedridden). An additional 28.6% had moderate to severe disease (strictly housebound). A total of 41.1% of ME/
CFS patients were bed- or housebound, and 86.8% of patients were unable to work full or part time the previous 
6 months.
HLA alleles associated with ME/CFS. In all patients and controls, we obtained 2nd field resolution geno-
types of HLA class I genes HLA -A, -B and -C and class II genes HLA -DRB1, -DQB1 and -DPB1. This resolution 
distinguishes HLA alleles that encode specific HLA proteins. No significant deviations from Hardy-Weinberg 
equilibrium were noted at any HLA loci, neither in the patient group nor in the control group (Supplementary 
Table S1). Allele frequencies for all observed HLA Class I and Class II alleles are presented in Supplementary 
Table S2. Global association tests for each HLA locus (Supplementary Table S3) were significant for HLA-C 
(p = 0.04) and HLA-DQB1 (p = 0.04). When comparing individual allele frequencies between patients and con-
trols, four HLA risk alleles emerged (Table 2): C*07:04 (OR = 2.1 [95% CI 1.4–3.1], pnc = 0.0001, pc = 0.001), 
B*57:01 (OR = 1.6 [95% CI 1.2–2.3], pnc = 0.004, pc < 0.05), DQB1*03:03 (OR = 1.5 [95% CI 1.1–2.0], pnc = 0.005, 
pc < 0.05) and B*44:02 (OR = 1.3 [95% CI 1.0–1.6], pnc = 0.03, pc = n.s.). In order to evaluate the dependency of 
these associations, we measured the degree of linkage disequilibrium (LD) between the four alleles within the 
patient group (Fig. 1). Strong LD was observed between C*07:04 and B*44:02 (D’ = 0.90) as well as between 
B*57:01 and DQB1*03:03 (D’ = 0.69), indicating that these alleles may occur on two distinct haplotypes. The first 
haplotype, C*07:04 - B*44:02, had an estimated frequency of 3.5% in the patient group and 1.7% in the control 
group, resulting in an OR of 2.1 (95% CI 1.4–3.1, pnc = 0.0002). The second haplotype, B*57:01 - DQB1*03:03, 
had an estimated frequency of 3.3% in the patient group and 2.0% in the control group, resulting in an OR of 
1.7 (95% CI 1.1–2.5 pnc = 0.01). To further evaluate which allele on each of the two haplotypes represents the 
Patients Controls
Mean age, years (min, max)a,b 39.5 (17, 79) 30.6 (19, 52)
Percentage femalesa,c 82.8 59.8
Mean age at diagnosis, years (min, 
max)d 34.7 (8, 65) —
Disease duration, percentage of patientse
1–5 years 18.1 —
5–10 years 45.5 —
10–15 years 26.4 —
>15 years 10.1 —
Disease severity, measured by activity assessment in DSQ79*, 
percentage of patientsf
Cat.1: Bedridden 12.5 —
Cat.2: Strictly housebound 28.6 —
Cat.3: Light housework 45.7 —
Cat.4: Able to work part time 12.2 —
Cat.5: Able to work full time 0.8 —
Cat.6: Handling some family 
obligations 0.3 —
Cat.7: Handling work and family 
obligations 0 —
Table 1. Demographic and clinical characteristics of ME/CFS patients and healthy controls. aValid number of 
controls: 4510. Valid number of patients: b426, c424, d345, e288, f385. *DePaul Symptom Questionnaire, question 
no. 7949,50: Cat.1: I am not able to work or do anything, and I am bedridden. Cat.2: I can walk around the house, 
but I cannot do light housework. Cat.3: I can do light housework, but I cannot work part-time. Cat.4: I can only 
work part time at work or on some family responsibilities. Cat.5: I can work full time, but I have no energy left 
for anything else. Cat.6: I can work full time and finish some family responsibilities but I have no energy left for 
anything else. Cat.7: I can do all work or family responsibilities without any problems with my energy.
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most significant association, we performed Svejgaard analyses between C*07:04 and B*44:02 as well as between 
B*57:01 and DQB1*03:03 (Supplementary Data Sheet S4). None of the two alleles on either of the two haplotypes 
reached significance when testing their independent association, which is not surprising due to the strong LD 
mentioned above. We report C*07:04 and DQB1*03:03 as tag alleles for the ME/CFS associations, since these 
alleles occur at the two loci initially showing global association.
We next wanted to make sure that these HLA associations were not due to gender differences between the 
cases and controls (82.8% vs 59.8% females, respectively). No significant gender differences were observed 
between the carrier frequencies of these alleles in either cases (Table 3) or controls (C*07:04 had a carrier fre-
quency of 3.7% in females and 4.0% in males; p = 0.6; DQB1*03:03 had a carrier frequency of 9.0% in females 
and 8.3% in males; p = 0.4). Furthermore, after stratifying cases and controls according to gender, heterogeneity 
was rejected (p > 0.5) between the OR values obtained for females only and males only, indicating no gender 
differences between the HLA associations observed in ME/CFS.
The two loci HLA-DRB1 and HLA-DQB1 are physically close, and exhibit particularly strong LD. In our data-
set, DQB1*03:03 occurred most frequently with DRB1*07:01. The haplotype DRB1*07:01 - DQB1*03:03 had 
estimated frequencies of 4.7% and 2.9% in the patient and control group, respectively (OR 1.7 [95% CI 1.2–2.3], 
pnc = 0.003). Among patients, this haplotype was without exception estimated to carry DQA1*02:01. Genotype 
data for the HLA-DQA1 locus was only obtained for patients, and was not available for the controls.
There were two alleles with a negative association with ME/CFS, suggesting a potential protection, namely 
B*08:01 (OR = 0.7 [95% CI 0.6–0.9], pnc = 0.01, pc = n.s.) and DPB1*02:01 (OR = 0.7 [95% CI 0.6–0.9], pnc = 0.02, 
pc = n.s.) (Table 2). These alleles were not in LD (D’ = −0.29), indicating that the associations are independent. 
The most frequent B*08:01 haplotype in Norway is the highly conserved so-called autoimmune and ancestral 
AH8.1 haplotype31 (C*07:01-B*08:01-DRB1*03:01-DQB1*02:01). This haplotype had reduced estimated fre-
quency in the patient group compared to the control group (8.2% vs. 10.3%, OR = 0.8, pnc = 0.06), albeit not 
significantly.
HLA risk allele carriers and clinical characteristics. The proportion of individuals carrying the allele 
C*07:04 was 7.7% in the patient group and 3.8% in the control group, while 12.7% of the patients and 8.7% of 
the controls carried DQB1*03:03 (Supplementary Data Sheet S4). The proportion of individuals carrying one or 
both of the two alleles was 19.2% in the patient group and 12.2% in the control group (OR 1.7, pnc = 0.00003, 95% 
CI[1.3–2.2]). Table 3 shows the distribution of clinical characteristics in the patient group, including stratification 
for C*07:04 and/or DQB1*03:03. Neither gender, initiating events, comorbidity of depression or fibromyalgia, 
nor AID or ME/CFS among 1st degree relatives were associated with the risk alleles. However, ME/CFS patients 
carrying one or both of the risk alleles had a significantly higher proportion of comorbid AID (OR = 2.3 [95% 
CI 1.2–4.3], pnc = 0.01). The frequency of comorbid AID was significantly increased also when stratifying for 
HLA allele ME/CFS, n (%) Controls, n (%) OR (95% CI) pnc pc*
C*07:04 33 (3.9) 172 (1.9) 2.1 (1.4–3.1) 0.0001 0.001
B*57:01 39 (4.6) 259 (2.9) 1.6 (1.2–2.3) 0.004 <0.05
DQB1*03:03 56 (6.6) 406 (4.5) 1.5 (1.1–2.0) 0.005 <0.05
B*44:02 105 (12.3) 904 (10.0) 1.3 (1.0–1.6) 0.03 0.3
B*08:01 83 (9.7) 1146 (12.7) 0.7 (0.6–0.9) 0.01 0.1
DPB1*02:01 78 (9.2) 1067 (11.8) 0.7 (0.6–1.0) 0.02 0.1
Table 2. HLA alleles showing association (pnc < 0.05) with ME/CFS in 426 patients and 4511 healthy controls. 
n = number of alleles. *Calculated by locus-wise Bonferroni multiple test correction.
Figure 1. Illustration of Linkage disequilibrium (LD) calculated as D’ values in the patient group between the 
four alleles with a significant association to ME/CFS. D’ measures the strength of LD between two alleles, and 
ranges from −1 to 0 for negative LD, and from 0 to 1 for positive LD. The number in each square is the D’ value 
between the two alleles listed diagonally above the square. Blue colors indicate the strength of LD, with darker 
colors for stronger LD.
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C*07:04 alone (OR = 2.9 [95% CI 1.2–6.6], pnc = 0.01), but not when stratifying for DQB1*03:03 alone (OR = 1.6 
[95% CI 0.8–3.4], pnc = n.s.). These patients, carrying HLA risk alleles, had the following AID, ordered by fre-
quency: Hashimoto’s thyreoiditis/hypothyreosis, psoriasis, rheumatoid arthritis, alopecia areata and Crohn’s dis-
ease or ulcerative colitis.
Discussion
In this project, we performed high resolution HLA genotyping by next generation sequencing (NGS) in 426 adult, 
Norwegian ME/CFS patients, diagnosed according to the Canadian Consensus Criteria2. There are no previous 
publications with comprehensive HLA genotyping by NGS in this patient group. We discovered two independent 
HLA associations, tagged by the alleles HLA-C*07:04 and HLA-DQB1*03:03.
To our knowledge, associations with HLA-C alleles have not previously been studied in ME/CFS. In 1994, 
Keller et al. performed serologic HLA-DR and DQ typing in 110 patients with Chronic fatigue immune dysfunc-
tion syndrome (CFIDS)22. The patients were diagnosed with the Holmes Criteria32, and CFIDS was defined as a 
subgroup with positive findings in viral reactivation patterns and B- and T-cell tests, indicating post-infectious 
debut and a certain degree of immune dysfunction. The authors found a significant association (OR = 1.8) with 
the serotype HLA-DQ3. Serologic HLA typing is of low resolution compared to genetic typing33. HLA-DQ3 cor-
responds to HLA-DQB1*03 in genetic nomenclature, where DQB1*03:03 is one of the three largest subgroups. 
Higher resolution HLA-DQB1 typing have been performed in two smaller cohorts (<58 patients), and even 
though statistically not significant, DQB1*03:03 was observed slightly more frequent among CFS patients, diag-
nosed with the Fukuda criteria, than among controls23,25. Hence, the findings in existing literature is compatible 
with the association between ME/CFS and DQB1*03:03 in our material.
HLA-B*08:01 showed reduced frequency in ME/CFS compared to controls in our material. This allele most 
often occur on the haplotype C*07:01-B*08:01-DRB1*03:01-DQB1*02:01, which was also less prevalent among 
ME/CFS patients in our material. This ancestral haplotype, AH8.1, is a risk factor for a wide variety of AID, 
including myasthenia gravis, systemic lupus erythematosus and coeliac disease31, but protective against rheuma-
toid arthritis34,35. In the existing literature on HLA and CFS, HLA-DRB1 is the locus most frequently studied. In 
four out of five studies, the frequency of DR3/DRB1*03 was lower in the patient group23–25,28, while in the fifth 
study the frequency was similar in both groups22. Hence, this haplotype seems truly less prevalent among ME/
CFS patients.
Some HLA associations previously reported in CFS are not supported by our results27,29. The often cited 
association with DQA1*01 reported by Smith et al.25 cannot be evaluated in our material since the HLA-DQA1 
locus was not genotyped in the control group. In our patient group, DQA1*01 occurred on haplotype with the 
following DQB1 alleles, ordered by frequency: DQB1*06:02, DQB1*05:01, DQB1*06:03, DQB1*06:04 and 
DQB1*05:03, and neither of these (pnc > 0.1, Supplementary Table S2), nor all combined (OR = 1.0, pnc = 0.6) 
were associated with ME/CFS.
The present HLA study in ME/CFS is to our knowledge the largest performed to date (other studies comprise 
≤ 110 CFS patients). Our study had 80% power to discover HLA-associations with OR ≥ 1.5 given an allele fre-
quency > 0.05. Interestingly, both C*07:04 and DQB1*03:03 remained significant after Bonferroni multiple test 
correction. Notably, we performed locus-wise multiple test correction, i.e. correcting for the number of alleles 
tested at each locus, since alleles at different HLA loci are in strong LD, and therefore do not represent independ-
ent tests. The Bonferroni method is considered a strict multiple test correction36, but on the other hand locus-wise 
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Table 3. Clinical characteristics of 426 ME/CFS patients: in total and stratified according to the presence of 
either DQB1*03:03 or C*07:04 or both.
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results need verification in independent cohorts. In general, established HLA associations are reproducible across 
different populations, but susceptibility loci can also vary between populations20,21,37,38. Therefore, HLA associa-
tions in ME/CFS should also be investigated in populations of different ancestry.
Both of the ME/CFS associations observed in our data set were evident at 2nd field resolution (i.e. C*07:04 
and DQB1*03:03), which distinguishes alleles encoding amino acid differences. Interestingly, the other C*07 and 
DQB1*03 alleles were not associated, emphasizing the importance of high resolution HLA genotyping.
We report C*07:04 and DQB1*03:03 as tag alleles for two independent HLA risk associations in ME/CFS, as 
these alleles are in linkage equilibrium (D’ = 0.06). However, they could still be markers for either one common, 
or two independently associated, variants outside the loci tested in this study. Alternatively, the associated alleles 
reported herein could constitute a functional relevance themselves. HLA class I alleles, like C*07:04, could influ-
ence disease risk through their interactions with CD8 positive cytotoxic T lymphocytes20,39. Disturbances in CD8 
positive T lymphocytes have been reported in ME/CFS, although the results are somewhat conflicting10. Another 
important function of HLA class I alleles is to serve as ligands for NK cell receptors. Altered numbers and func-
tion of NK cells have been reported by several independent researchers in ME/CFS14,15,40. The other associated 
allele, DQB1*03:03, is an HLA class II allele, which is also interesting in regard to the hypothesis of autoimmun-
ity in ME/CFS. In certain well studied AID, associated HLA class II alleles have been shown to exhibit unique 
peptide binding properties, as well as HLA-TCR restriction, directly influencing the acquired immune response, 
e.g. with the production of specific auto-antibodies41. A dysregulated activity of CD4 positive T lymphocytes, the 
principal cell type interfering with HLA class II alleles, have been discussed as a central mechanism in ME/CFS42. 
Several studies report increased levels of specific auto-antibodies in ME/CFS patients43, e.g. to neurotransmitter 
receptors, although most of these lack verification in additional cohorts.
Another interesting question is whether these HLA associations are driven by subgroups of patients, and thereby 
representing stronger risk alleles. This is a relevant aspect in a complex disease like ME/CFS, where different causal 
mechanisms may be at play in different subgroups. In our study, ME/CFS patients carrying HLA risk alleles had a 
significantly higher comorbidity of established AID. We are not aware of any publications reporting associations 
between C*07:04 or DQB1*03:03 and the AID affecting some of our patients. Therefore, it is unlikely that the 
associations in our material are driven by HLA associations with already established AID. Familial aggregation is 
observed for many specific AID, as well as for autoimmunity in general44. 1st degree relatives of ME/CFS patients 
in our study have a high prevalence of AID (Table 3). These observations could potentially be due to an element of 
autoimmunity in ME/CFS, or within a subgroup. No other patient characteristics were dominant among the ME/
CFS patients with HLA risk alleles, specifically neither self-reported infectious onset nor current disease severity. It 
can be argued that the lack of validity of self-reported data precludes the detection of possible subgroup identifiers.
In conclusion, we report novel HLA associations in a large cohort of ME/CFS patients fulfilling the Canadian 
Consensus Criteria, thereby supporting the involvement of the immune system in the ME/CFS pathogenesis.
Materials and Methods
This study is approved by the Norwegian Regional Committees for Medical and Health Research Ethics45. All 
methods and data handling were performed according to relevant national and institutional regulations and 
guidelines. All patients gave informed consent. In three cases, written consent was given by a close relative due to 
the patient being severely ill and unable to sign. A total of 426 adult, Norwegian ME/CFS patients were included. 
All had been diagnosed in Norway according to the 2003 Canadian Consensus Criteria2, except for four patients 
where the similarly strict 2010 International Consensus Criteria3 were applied. There were three separate recruit-
ment groups for ME/CFS patients: 214 patients were recruited from recent and ongoing trials with Rituximab46,47 
and Cyclophosphamide (Rekeland IG et al., submitted, NCT02444091); 116 patients were recruited from the 
CFS/ME biobank at Oslo University Hospital; 96 patients were recruited via announcements in patient networks, 
including patient organizations. Patients from the latter two groups were not included in clinical trials. Duplicates 
within or between the three recruitment groups were excluded. All patients provided the identity of any 1st, 2nd 
or 3rd degree relatives with ME/CFS, and we excluded close relatives to ensure that only one patient per extended 
family was included. Norwegian ethnicity was ensured by evaluation of sur- and family names of all patients, 
country of birth of parents and grandparents as well as self-perceived ethnicity. The control group consisted 
of 4511 ethnically matched, healthy individuals drawn from the Norwegian Bone Marrow Donor Registry48. 
Clinical information was collected for the ME/CFS patients through questionnaires completed by patients or 
close relatives. The categories applied in this study were gender, age at diagnosis, initiating events, disease dura-
tion and severity, comorbidities and family history. Most of the questions were based on the DePaul Symptom 
Questionnaire49,50. Infection or vaccination as initiating event was self-reported, and in many cases, the time from 
event to symptom debut was not specified. The disease severity was assessed with self-reported activity level dur-
ing the previous 6 months, as stated through the DePaul Symptom Questionnaire, question no. 79.
HLA genotyping by next generation sequencing. In 426 ME/CFS patients, we performed high resolu-
tion, targeted, next generation sequencing (NGS) of HLA class I genes HLA -A, -B and -C and class II genes HLA 
-DRB1, -DQB1, -DPB1, -DQA1. Amplification and library preparation were performed with kits from GenDx 
(Utrecht, The Netherlands) and Illumina (San Diego, USA), 2 ×150 bp paired-end sequencing was performed by 
The Norwegian Sequencing Centre with Illumina MiSeq Reagent Kit v2 (300-cycles), and HLA genotypes were 
obtained by analyzing sequencing reads with NGSengine from GenDx, using the IMGT/HLA Database51. The 
median sequencing depth was above 150 reads per called base. The 4511 healthy Norwegian controls had pre-
viously been HLA typed by NGS52. Both patient and control genotypes were analyzed at 2nd field resolution for 
HLA -A, -B, -C, -DRB1, -DQB1 and -DPB1. HLA alleles can be genotyped at resolution level from 1st field to 4th 
field. 2nd field resolution distinguishes alleles that encode amino acid differences, i.e. specific HLA proteins, and 
is therefore of great biological relevance. The genotyping success exceeded 99% in the patient group and 99.9% 
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in the control group for all loci. In the control group, alleles were originally identified at a G group resolution, 
and certain alleles from the patient group were therefore converted to avoid typing method bias (Supplementary 
Table S5).
Data analyses were performed in Unphased 3.0.10 and Pypop 0.7.053,54. Assessment of Hardy-Weinberg 
equilibrium was performed with a chi-square test with a significance level of 0.05. Haplotype frequencies were 
estimated with an expectation-maximization method for unknown gametic phase. Global associations for each 
locus were calculated with a likelihood ratio test, with a rare allele frequency threshold of 0.01. Genetic associ-
ations were investigated on allelic and haplotypic levels, and ORs with 95% confidence intervals (95% CI) were 
calculated with Woolf ’s formula comprising Haldane’s correction. Risk allele ORs were calculated also with gen-
der stratification, and homogeneity tests were performed with the logit-based estimator. LD calculations and 
Svejgaard tests were carried out to examine the degree of independence between the associated alleles55. The 
LD measure D’ was calculated according to the formula D’ = D/Dmax, where Dmax = min [pA(1-pB), (1-pA)pB] for 
D > 0, Dmax = min [pApB, (1-pA)(1-pB)] for D < 0, D is the standard mathematical definition of LD between alleles 
A and B56, and p is the frequency of the stated allele. Because of the comparison of multiple allele frequencies we 
performed locus-wise Bonferroni correction. For each locus, non-corrected p-values were multiplied by the total 
number of alleles detected at that locus, excluding alleles with a frequency less than 3% in both the control group 
and the patient group. The significance level was 0.05. Only haplotypes consisting of associated alleles were inves-
tigated, and multiple test correction was therefore not applied on the haplotypic level.
Investigation of clinical data. The clinical information was gathered separately for each of the three 
recruitment groups, controlled in one common database, and exported to SPSS57 for statistical analyses. The 
patient group was stratified according to the presence of specific HLA alleles, and eight dichotomized clinical 
variables were assessed with OR calculation by binary logistic regression, and chi-square significance testing.
Restrictions on the availability of material. Individual genotypes of patients are not made available due 
to Norwegian privacy regulations and laws.
Received: 2 September 2019; Accepted: 3 March 2020;
Published: xx xx xxxx
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